Evaluating the Impact of Applying Personal Glucose Targets in a Closed-Loop System for People With Type 1 Diabetes.

algorithm glucose control hybrid closed-loop personal glucose target type 1 diabetes

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
20 Dec 2022
Historique:
entrez: 21 12 2022
pubmed: 22 12 2022
medline: 22 12 2022
Statut: aheadofprint

Résumé

CamAPS FX is a hybrid closed-loop smartphone app used to manage type one diabetes. The closed-loop algorithm has a default target glucose of 5.8 mmol/L (104.5 mg/dL), but users can select personal glucose targets (adjustable between 4.4 mmol/L and 11.0 mmol/L [79 mg/dL and 198 mg/dL, respectively]). In this post-hoc analysis, we evaluated the impact of personal glucose targets on glycemic control using data from participants in five randomized controlled trials. Personal glucose targets were widely used, with 20.3% of all days in the data set having a target outside the default target bin (5.5-6.0 mmol/L [99-108 mg/dL]). Personal glucose targets >6.5 mmol/L (117 mg/dL) were associated with significantly less time in target range (3.9-10.0 mmol/L [70-180 mg/dL]; 6.5-7.0 mmol/L [117-126 mg/dL]: mean difference = -3.2 percentage points [95% CI: -5.3 to -1.2; Discrete study populations showed differences in glucose control when applying similar personal targets.

Sections du résumé

BACKGROUND BACKGROUND
CamAPS FX is a hybrid closed-loop smartphone app used to manage type one diabetes. The closed-loop algorithm has a default target glucose of 5.8 mmol/L (104.5 mg/dL), but users can select personal glucose targets (adjustable between 4.4 mmol/L and 11.0 mmol/L [79 mg/dL and 198 mg/dL, respectively]).
METHOD METHODS
In this post-hoc analysis, we evaluated the impact of personal glucose targets on glycemic control using data from participants in five randomized controlled trials.
RESULTS RESULTS
Personal glucose targets were widely used, with 20.3% of all days in the data set having a target outside the default target bin (5.5-6.0 mmol/L [99-108 mg/dL]). Personal glucose targets >6.5 mmol/L (117 mg/dL) were associated with significantly less time in target range (3.9-10.0 mmol/L [70-180 mg/dL]; 6.5-7.0 mmol/L [117-126 mg/dL]: mean difference = -3.2 percentage points [95% CI: -5.3 to -1.2;
CONCLUSIONS CONCLUSIONS
Discrete study populations showed differences in glucose control when applying similar personal targets.

Identifiants

pubmed: 36540007
doi: 10.1177/19322968221145184
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19322968221145184

Auteurs

Mustafa Fattah (M)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Charlotte K Boughton (CK)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Julia Ware (J)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Department of Paediatrics, University of Cambridge, Cambridge, UK.

Janet M Allen (JM)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Sara Hartnell (S)

Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Malgorzata E Willinska (ME)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Department of Paediatrics, University of Cambridge, Cambridge, UK.

Ajay Thankamony (A)

Department of Paediatrics, University of Cambridge, Cambridge, UK.

Carine de Beaufort (C)

Diabetes & Endocrine Care Clinique Pediatrique, Pediatric Clinic/Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-Belval, Luxembourg.

Fiona M Campbell (FM)

Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, UK.

Elke Fröhlich-Reiterer (E)

Department of Pediatrics, Medical University of Graz, Graz, Austria.

Sabine E Hofer (SE)

Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.

Thomas M Kapellen (TM)

Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany.

Birgit Rami-Merhar (B)

Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.

Atrayee Ghatak (A)

Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Tabitha L Randell (TL)

Nottingham Children's Hospital, Nottingham, UK.

Rachel E J Besser (REJ)

Department of Paediatrics, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.

Daniela Elleri (D)

Royal Hospital for Children & Young People, Edinburgh, UK.

Nicola Trevelyan (N)

Southampton Children's Hospital, Southampton, UK.

Louise Denvir Md (L)

Nottingham Children's Hospital, Nottingham, UK.

Nikki Davis (N)

Southampton Children's Hospital, Southampton, UK.

Lia Bally (L)

Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Hood Thabit (H)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Lalantha Leelarathna (L)

Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Mark L Evans (ML)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Julia K Mader (JK)

Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Roman Hovorka (R)

Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Classifications MeSH